Shenzhen, China – This study is led by Dr. Weiren Huang (Shenzhen Institute of Translational Medicine, the First Affiliated Hospital of Shenzhen University). In clinical practice, drug resistance poses a significant challenge in cancer treatment. The process of developing resistance is regulated by complex decision-making pathways and genetic signal networks....
research News
SECAUCUS, N.J. — A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer’s disease (AD) is likely not the cause of patients’ mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics (NYSE:...
Canberra, Australia – A protein in the immune system programmed to protect the body from fungal infections is also responsible for exacerbating the severity of certain autoimmune diseases such as irritable bowel disease (IBS), type 1 diabetes, eczema and other chronic disorders, new research from The Australian National University (ANU)...
Reston, VA — PET imaging with 68Ga-FAPI can more effectively detect and stage pancreatic cancer as compared with 18F-FDG imaging or contrast-enhanced CT, according to new research published in the December issue of The Journal of Nuclear Medicine. In a head-to-head study, 68Ga-FAPI detected more pancreatic tumors on a per-lesion, per-patient, or per-region...
BETHESDA, Md.– Gain Therapeutics, Inc., a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage...
SHANGHAI, China — Gannex Pharma Co., Ltd. a wholly-owned company of Ascletis Pharma Inc., announces today positive interim results from the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 tablet for treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). ASC41 is liver-targeting and highly THRβ-selective. Once-daily...
Sydney, Australia – Researchers have discovered how the mechanical properties of tumours can prime cancer cells to better survive their spread to other organs. A metabolic ‘survival switch’ controlled by the stiffness of triple-negative breast tumours can significantly influence how successfully their cancerous cells spread to other organs, according to...
New Haven, CT – Gaucher disease treatment has come a long way in the past three decades. The United States Food and Drug Administration (FDA) approved the first enzyme replacement therapy (ERT) in 1991. That first approval opened the door for other ERT treatments and paved the road for substrate...
YOGIN, South Korea — GC Biopharma Corp today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as “GC5107,” for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency (PI). The ALYGLO pivotal...
Uppsala, Sweden – Women with a type of ovarian cancer known as germ cell tumors have a worse prognosis than men with similar tumours, i.e. testicular cancer. After five years with the disease, 98 percent of men were alive while the survival rate for women was only 85 percent. This...